[
    "titumor\u00a0activity\u00a0of\u00a0immune\u00a0cells.\u00a0Recent\u00a0studies\u00a0also\u00a0showed\u00a0that\u00a0B7-H3\u00a0can\u00a0influence\u00a0cancer\u00a0progression\u00a0beyond\u00a0the\u00a0immune\u00a0regulatory\u00a0roles.\u00a0Given\u00a0the\u00a0significant\u00a0role\u00a0for\u00a0B7H3\u00a0in\u00a0immune\u00a0checkpoint\u00a0regulation,\u00a0there\u00a0is\u00a0a\u00a0need\u00a0in\u00a0the\u00a0art\u00a0for\u00a0the\u00a0development\u00a0of\u00a0therapeutic\u00a0molecules\u00a0and\u00a0methods\u00a0to\u00a0modulate\u00a0B7H3-mediated\u00a0immune\u00a0cell\u00a0regulation\u00a0for\u00a0immune\u00a0therapy\u00a0and\u00a0cancer\u00a0treatment.</p><heading id=\"h0003\">SUMMARY\u00a0OF\u00a0THE\u00a0INVENTION</heading><p id=\"p0005\" num=\"0005\">The\u00a0present\u00a0disclosure\u00a0provides\u00a0isolated\u00a0monoclonal\u00a0antibodies\u00a0and\u00a0antibody\u00a0derivatives\u00a0that\u00a0bind\u00a0specifically\u00a0to\u00a0B7H3\u00a0with\u00a0high\u00a0affinity,\u00a0including\u00a0monospecific\u00a0anti-B7H3\u00a0antibodies\u00a0and\u00a0multispecific\u00a0antibodies\u00a0that\u00a0binds\u00a0to\u00a0B7H3\u00a0and\u00a0one\u00a0or\u00a0more\u00a0additional\u00a0target.\u00a0In\u00a0certain\u00a0embodiments,\u00a0an\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0disclosed\u00a0herein\u00a0comprises\u00a0a\u00a0single\u00a0domain\u00a0antibody\u00a0that\u00a0binds\u00a0to\u00a0B7H3.\u00a0This\u00a0disclosure\u00a0further\u00a0provides\u00a0methods\u00a0of\u00a0making\u00a0and\u00a0using\u00a0antibodies\u00a0and\u00a0antibody\u00a0derivatives\u00a0disclosed\u00a0herein\u00a0and\u00a0pharmaceutical\u00a0compositions\u00a0comprising\u00a0the\u00a0same,\u00a0e.g.,\u00a0for\u00a0treating\u00a0diseases\u00a0and\u00a0disorders,\u00a0e.g.,\u00a0cancer.\u00a0The\u00a0invention\u00a0is\u00a0based,\u00a0in\u00a0part,\u00a0on\u00a0the\u00a0discovery\u00a0of\u00a0novel\u00a0single\u00a0domain\u00a0antibodies\u00a0that\u00a0bind\u00a0to\u00a0B7H3,\u00a0which\u00a0can\u00a0target\u00a0a\u00a0tumor\u00a0cell\u00a0and/or\u00a0increase\u00a0an\u00a0immune\u00a0response\u00a0against\u00a0a\u00a0tumor\u00a0cell\u00a0and\u00a0thereby\u00a0provide\u00a0improved\u00a0anti-tumor\u00a0efficacy.\t\t\t\t<!-- 1 -->\n\t\t\t\t\n</p><p id=\"p0006\" num=\"0006\">The\u00a0present\u00a0disclosure\u00a0provides\u00a0an\u00a0antibody\u00a0that\u00a0binds\u00a0to\u00a0B7H3,\u00a0comprising\u00a0a\u00a0single\u00a0domain\u00a0antibody\u00a0that\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a01x10<sup>-7</sup>\u00a0M\u00a0or\u00a0less.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a05x10<sup>-8</sup>\u00a0M\u00a0or\u00a0less.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a01x10<sup>-8</sup>\u00a0M\u00a0or\u00a0less.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0between\u00a0about\u00a01x10<sup>-10</sup>\u00a0M\u00a0and\u00a0about\u00a05x10<sup>-8</sup>\u00a0M.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0comprises\u00a0a\u00a0VHH.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0or\u00a0the\u00a0VHH\u00a0comprises\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0(VH)\u00a0.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0cross-competes\u00a0for\u00a0binding\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0reference\u00a0anti-B7H3\u00a0single\u00a0domain\u00a0antibody\u00a0comprising\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0comprising:\u00a0a)\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR1\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a01,\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR2\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a02,\u00a0and\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR3\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a03,\u00a0b)\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR1\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a05,\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR2\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a06,\u00a0and\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR3\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a07,\u00a0c)\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR1\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a09,\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR2\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a010,\u00a0and\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR3\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a011,\u00a0d)\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR1\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0",
    "logy\u00a0of\u00a0Monoclonal\u00a0Antibodies,\u00a0vol.\u00a0113,\u00a0Rosenburg\u00a0and\u00a0Moore\u00a0eds.,\u00a0Springer-Verlag,\u00a0New\u00a0York,\u00a0pp.\u00a0269-315\u00a0(1994)\u00a0.</p><p id=\"p0048\" num=\"0048\">An\u00a0\u201cacceptor\u00a0human\u00a0framework\u201d\u00a0or\u00a0\u201chuman\u00a0framework\u201d\u00a0for\u00a0the\u00a0purposes\u00a0herein\u00a0is\u00a0a\u00a0framework\u00a0comprising\u00a0the\u00a0amino\u00a0acid\u00a0sequence\u00a0of\u00a0a\u00a0light\u00a0chain\u00a0variable\u00a0domain\u00a0(VL)\u00a0framework\u00a0or\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0domain\u00a0(VH)\u00a0framework\u00a0derived\u00a0from\u00a0a\u00a0human\u00a0immunoglobulin\u00a0framework\u00a0or\u00a0a\u00a0human\u00a0consensus\u00a0framework.\u00a0An\u00a0acceptor\u00a0human\u00a0framework\u00a0\u201cderived\u00a0from\u201d\u00a0a\u00a0human\u00a0immunoglobulin\u00a0framework\u00a0or\u00a0a\u00a0human\u00a0consensus\u00a0framework\u00a0may\u00a0comprise\u00a0the\u00a0same\u00a0amino\u00a0acid\u00a0sequence\u00a0thereof,\u00a0or\u00a0it\u00a0may\u00a0contain\u00a0amino\u00a0acid\u00a0sequence\u00a0changes.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0number\u00a0of\u00a0amino\u00a0acid\u00a0changes\u00a0are\u00a010\u00a0or\u00a0less,\u00a09\u00a0or\u00a0less,\u00a08\u00a0or\u00a0less,\u00a07\u00a0or\u00a0less,\u00a06\u00a0or\u00a0less,\u00a05\u00a0or\u00a0less,\u00a04\u00a0or\u00a0less,\u00a03\u00a0or\u00a0less,\u00a0or\u00a02\u00a0or\u00a0less.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0VL\u00a0acceptor\u00a0human\u00a0framework\u00a0is\u00a0identical\u00a0in\u00a0sequence\u00a0to\u00a0the\u00a0VL\u00a0human\u00a0immunoglobulin\u00a0framework\u00a0sequence\u00a0or\u00a0human\u00a0consensus\u00a0framework\u00a0sequence.\t\t\t\t<!-- 12 -->\n\t\t\t\t\n</p><p id=\"p0049\" num=\"0049\">\u201cAffinity\u201d\u00a0refers\u00a0to\u00a0the\u00a0strength\u00a0of\u00a0the\u00a0sum\u00a0total\u00a0of\u00a0noncovalent\u00a0interactions\u00a0between\u00a0a\u00a0single\u00a0binding\u00a0site\u00a0of\u00a0a\u00a0molecule\u00a0(e.g.,\u00a0an\u00a0antibody)\u00a0and\u00a0its\u00a0binding\u00a0partner\u00a0(e.g.,\u00a0an\u00a0antigen)\u00a0.\u00a0Unless\u00a0indicated\u00a0otherwise,\u00a0as\u00a0used\u00a0herein,\u00a0\u201cbinding\u00a0affinity\u201d\u00a0refers\u00a0to\u00a0intrinsic\u00a0binding\u00a0affinity\u00a0which\u00a0reflects\u00a0a\u00a01:\u00a01\u00a0interaction\u00a0between\u00a0members\u00a0of\u00a0a\u00a0binding\u00a0pair\u00a0(e.g.,\u00a0antibody\u00a0and\u00a0antigen)\u00a0.\u00a0The\u00a0affinity\u00a0of\u00a0a\u00a0molecule\u00a0X\u00a0for\u00a0its\u00a0partner\u00a0Y\u00a0can\u00a0generally\u00a0be\u00a0represented\u00a0by\u00a0the\u00a0dissociation\u00a0constant\u00a0(KD)\u00a0.\u00a0Affinity\u00a0can\u00a0be\u00a0measured\u00a0by\u00a0common\u00a0methods\u00a0known\u00a0in\u00a0the\u00a0art,\u00a0including\u00a0those\u00a0described\u00a0herein.\u00a0Specific\u00a0illustrative\u00a0and\u00a0exemplary\u00a0embodiments\u00a0for\u00a0measuring\u00a0binding\u00a0affinity\u00a0are\u00a0described\u00a0in\u00a0the\u00a0following.</p><p id=\"p0050\" num=\"0050\">An\u00a0\u201caffinity\u00a0matured\u201d\u00a0antibody\u00a0refers\u00a0to\u00a0an\u00a0antibody\u00a0with\u00a0one\u00a0or\u00a0more\u00a0alterations\u00a0in\u00a0one\u00a0or\u00a0more\u00a0CDRs\u00a0or\u00a0hypervariable\u00a0regions\u00a0(HVRs)\u00a0,\u00a0compared\u00a0to\u00a0a\u00a0parent\u00a0antibody\u00a0which\u00a0does\u00a0not\u00a0possess\u00a0such\u00a0alterations,\u00a0which\u00a0alterations\u00a0provide\u00a0improved\u00a0affinity\u00a0of\u00a0the\u00a0antibody\u00a0for\u00a0antigen.</p><p id=\"p0051\" num=\"0051\">\u201cB7H3\u201d\u00a0,\u00a0\u201cB7H3\u00a0protein\u201d\u00a0or\u00a0\u201cB7H3\u00a0polypeptide\u201d\u00a0as\u00a0used\u00a0herein,\u00a0refers\u00a0to\u00a0any\u00a0B7H3\u00a0polypeptide\u00a0from\u00a0any\u00a0vertebrate\u00a0source,\u00a0including\u00a0mammals\u00a0such\u00a0as\u00a0primates\u00a0(e.g.,\u00a0humans\u00a0and\u00a0cynomolgus\u00a0monkeys)\u00a0,\u00a0or\u00a0any\u00a0fragment\u00a0thereof,\u00a0and\u00a0may\u00a0optionally\u00a0comprise\u00a0up\u00a0to\u00a0one,\u00a0up\u00a0to\u00a0two,\u00a0up\u00a0to\u00a0three,\u00a0up\u00a0to\u00a0four,\u00a0up\u00a0to\u00a0five,\u00a0up\u00a0to\u00a0six,\u00a0up\u00a0to\u00a0seven,\u00a0up\u00a0to\u00a0eight,\u00a0up\u00a0to\u00a0nine\u00a0or\u00a0up\u00a0to\u00a0ten\u00a0amino\u00a0acid\u00a0substitutions,\u00a0additions\u00a0and/or\u00a0deletions.\u00a0The\u00a0term\u00a0encompasses\u00a0full-length,\u00a0unprocessed\u00a0B7H3\u00a0as\u00a0well\u00a0as\u00a0any\u00a0form\u00a0of\u00a0B7H3\u00a0that\u00a0results\u00a0from\u00a0processing\u00a0in\u00a0the\u00a0cell.\u00a0The\u00a0term\u00a0also\u00a0encompasses\u00a0naturally\u00a0occurring\u00a0variants\u00a0of\u00a0B7H3,\u00a0e.g.,\u00a0splice\u00a0variants\u00a0or\u00a0allelic\u00a0variants.\u00a0In\u00a0certain\u00a0embodiments,\u00a0a\u00a0B7H3\u00a0polypeptide\u00a0comprises\u00a0or\u00a0has\u00a0an\u00a0amino\u00a0acid\u00a0sequence\u00a0that\u00a0is\u00a0at\u00a0least\u00a0about\u00a080%,\u00a0at\u00a0least\u00a0about\u00a085%,\u00a0at\u00a0least\u00a0about\u00a090%,\u00a0at\u00a0least\u00a0about\u00a095%,\u00a0at\u00a0least\u00a0about\u00a096%,\u00a0at\u00a0least\u00a0about\u00a097%,\u00a0at\u00a0least\u00a0about\u00a098%,\u00a0at\u00a0least\u00a0about\u00a099%or\u00a0at\u00a0least\u00a0about\u00a0100%homologous\u00a0or\u00a0identical\u00a0to\u00a0the\u00a0sequence\u00a0having\u00a0a\u00a0NCBI\u00a0Reference\u00a0No:\u00a0NP_001316557.1,\u00a0NP_001316558.1,\u00a0NP_079516.1\u00a0or\u00a0NP_001019907.1\u00a0(homology\u00a0herein\u00a0may\u00a0be\u00a0determined\u00a0using\u00a0standard\u00a0software\u00a0such\u00a0as\u00a0BLAST\u00a0or\u00a0FASTA)\u00a0.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0B7H3\u00a0polypeptide\u00a0comprises\u00a0or\u00a0has\u00a0an\u00a0amino\u00a0acid\u00a0sequence\u00a0that\u00a0is\u00a0the\u00a0entirety\u00a0or\u00a0a\u00a0consecutive\u00a0portion\u00a0of\u00a0SEQ\u00a0ID\u00a0NO:\u00a083.</p><p id=\"p0052\" num=\"0052\">The\u00a0term\u00a0\u201cECD\u00a0of\u00a0B7H3\u201d\u00a0refers\u00a0to\u00a0an\u00a0extracellular\u00a0domain\u00a0of\u00a0B7H3.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0ECD\u00a0of\u00a0an\u00a0exemplary\u00a0B7H3\u00a0polypeptide\u00a0can\u00a0comprise\u00a0the\u00a0amino\u00a0acid\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a084.</p><p id=\"p0053\" num=\"0053\">The\u00a0terms\u00a0\u201canti-B7H3\u00a0antibody\u201d\u00a0and\u00a0\u201can\u00a0antibody\u00a0that\u00a0binds\u00a0to\u00a0B7H3\u201d\u00a0refer\u00a0to\u00a0an\u00a0antibody\u00a0that\u00a0is\u00a0capable\u00a0of\u00a0binding\u00a0to\u00a0B7H3\u00a0with\u00a0sufficient\u00a0affinity\u00a0such\u00a0that\u00a0the\u00a0antibody\u00a0is\u00a0useful\u00a0as\u00a0a\u00a0diagnostic\u00a0and/or\u00a0therapeutic\u00a0agent\u00a0for\u00a0targeting\u00a0B7H3.\u00a0In\u00a0one\u00a0embodiment,\u00a0the\u00a0extent\u00a0of\u00a0binding\u00a0of\u00a0an\u00a0anti-B7H3\u00a0antibody\u00a0to\u00a0an\u00a0unrelated,\u00a0non-B7H3\u00a0protein\u00a0is\u00a0less\u00a0than\u00a0about\u00a0\t\t\t\t<!-- 13 -->\n\t\t\t\t\n10%of\u00a0the\u00a0binding\u00a0of\u00a0the\u00a0antibody\u00a0to\u00a0B7H3\u00a0as\u00a0measured,\u00a0e.g.,\u00a0by\u00a0a\u00a0<img id=\"idf0001\" path=\"PCTCN2023120292-ftappb-I100001.jpg\" file=\"https://surechembl.org/api/assets/attachment/1228453345/WO/20240328/A1/002024/06/13/06/PCTCN2023120292-ftappb-I100001.jpg\"/>surface\u00a0plasmon\u00a0resonance\u00a0assay.\u00a0In\u00a0certain\u00a0embodiments,\u00a0an\u00a0antibody\u00a0that\u00a0binds\u00a0to\u00a0B7H3\u00a0has\u00a0a\u00a0dissociation\u00a0constant\u00a0(KD)\u00a0of&lt;about\u00a01\u03bcM,\u00a0&lt;about\u00a0100\u00a0nM,\u00a0&lt;about\u00a010\u00a0nM,\u00a0&lt;about\u00a01\u00a0nM,\u00a0&lt;about\u00a00.1\u00a0nM,\u00a0&lt;about\u00a00.01\u00a0nM,\u00a0or&lt;about\u00a00.001\u00a0nM\u00a0(e.g.,\u00a010<sup>-8</sup>\u00a0M\u00a0or\u00a0less,\u00a0e.g.,\u00a0from\u00a010<sup>-8</sup>\u00a0M\u00a0to\u00a010<sup>-12</sup>M,\u00a0e.g.,\u00a0from\u00a010<sup>-9</sup>M\u00a0to\u00a010<sup>-10</sup>M)\u00a0.\u00a0In\u00a0certain\u00a0embodiments,\u00a0an\u00a0anti-B7H3\u00a0antibodybinds\u00a0to\u00a0an\u00a0epitope\u00a0of\u00a0B7H3\u00a0that\u00a0is\u00a0conserved\u00a0among\u00a0B7H3\u00a0from\u00a0different\u00a0species.\u00a0In\u00a0certain\u00a0embodiments,\u00a0an\u00a0anti-B7H3\u00a0antibody\u00a0binds\u00a0to\u00a0an\u00a0epitope\u00a0on\u00a0B7H3\u00a0that\u00a0is\u00a0in\u00a0the\u00a0ECD\u00a0of\u00a0the\u00a0protein.</p><p id=\"p0054\" num=\"0054\">The\u00a0term\u00a0\u201cchimeric\u201d\u00a0antibody\u00a0refers\u00a0to\u00a0an\u00a0antibody\u00a0in\u00a0which\u00a0a\u00a0portion\u00a0of\u00a0the\u00a0heavy\u00a0and/or\u00a0light\u00a0chain\u00a0is\u00a0derived\u00a0from\u00a0a\u00a0particular\u00a0source\u00a0or\u00a0species,\u00a0while\u00a0the\u00a0remainder\u00a0of\u00a0the\u00a0heavy\u00a0and/or\u00a0light\u00a0chain\u00a0is\u00a0derived\u00a0from\u00a0a\u00a0different\u00a0source\u00a0or\u00a0species.\u00a0In\u00a0certain\u00a0embodiments,\u00a0a\u00a0chimeric\u00a0antibody\u00a0disclosed\u00a0herein\u00a0comprises\u00a0a\u00a0camelid\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0and\u00a0a\u00a0human\u00a0Fc\u00a0region.</p><p id=\"p0055\" num=\"0055\">As\u00a0used\u00a0herein,\u00a0the\u00a0term\u00a0\u201cCDR\u201d\u00a0or\u00a0\u201ccomplementarity\u00a0determining\u00a0region\u201d\u00a0is\u00a0intended\u00a0to\u00a0mean\u00a0the\u00a0non-contiguous\u00a0antigen\u00a0combining\u00a0sites\u00a0within\u00a0the\u00a0variable\u00a0region\u00a0of\u00a0a\u00a0heavy\u00a0chain\u00a0and/or\u00a0a\u00a0light\u00a0chain.\u00a0These\u00a0particular\u00a0regions\u00a0have\u00a0been\u00a0described\u00a0by\u00a0Kabat\u00a0et\u00a0al.,\u00a0J.\u00a0Biol.\u00a0Chem.\u00a0252:\u00a06609-6616\u00a0(1977)\u00a0;\u00a0Kabat\u00a0et\u00a0al.,\u00a0U.S.\u00a0Dept.\u00a0of\u00a0Health\u00a0and\u00a0Human\u00a0Services,\u00a0\u201cSequences\u00a0of\u00a0proteins\u00a0of\u00a0immunological\u00a0interest\u201d\u00a0(1991)\u00a0;\u00a0Chothia\u00a0et\u00a0al.,\u00a0J.\u00a0Mol.\u00a0Biol.\u00a0196:\u00a0901-917\u00a0(1987)\u00a0;\u00a0Al-Lazikani\u00a0B.\u00a0et\u00a0al.,\u00a0J.\u00a0Mol.\u00a0Biol.,\u00a0273:\u00a0927-948\u00a0(1997)\u00a0;\u00a0MacCallum\u00a0et\u00a0al.,\u00a0J.\u00a0Mol.\u00a0Biol.\u00a026",
    "91)\u00a0;\u00a0Capel\u00a0et\u00a0al.,\u00a0Immunomethods\u00a04:\u00a025-34\u00a0(1994)\u00a0;\u00a0and\u00a0de\u00a0Haas\u00a0et\u00a0al.,\u00a0J.\u00a0Lab.\u00a0Clin.\u00a0Med.\u00a0126:\u00a0330-41\u00a0(1995)\u00a0.\u00a0Other\u00a0FcRs,\u00a0including\u00a0those\u00a0to\u00a0be\u00a0identified\u00a0in\u00a0the\u00a0future,\u00a0are\u00a0encompassed\u00a0by\u00a0the\u00a0term\u00a0\u201cFcR\u201d\u00a0herein.</p><p id=\"p0077\" num=\"0077\">The\u00a0term\u00a0\u201cepitope\u201d\u00a0as\u00a0used\u00a0herein\u00a0refers\u00a0to\u00a0the\u00a0specific\u00a0group\u00a0of\u00a0atoms\u00a0or\u00a0amino\u00a0acids\u00a0on\u00a0an\u00a0antigen\u00a0to\u00a0which\u00a0an\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0binds.\u00a0Two\u00a0antibodies\u00a0or\u00a0antigen-binding\u00a0moieties\u00a0may\u00a0bind\u00a0the\u00a0same\u00a0epitope\u00a0within\u00a0an\u00a0antigen\u00a0if\u00a0they\u00a0exhibit\u00a0competitive\u00a0binding\u00a0for\u00a0the\u00a0antigen.\t\t\t\t<!-- 18 -->\n\t\t\t\t\n</p><p id=\"p0078\" num=\"0078\">As\u00a0use\u00a0herein,\u00a0the\u00a0terms\u00a0\u201cspecifically\u00a0binds,\u00a0\u201d\u00a0\u201cspecifically\u00a0recognizing,\u00a0\u201d\u00a0and\u00a0\u201cis\u00a0specific\u00a0for\u201d\u00a0refer\u00a0to\u00a0measurable\u00a0and\u00a0reproducible\u00a0interactions,\u00a0such\u00a0as\u00a0binding\u00a0between\u00a0a\u00a0target\u00a0and\u00a0an\u00a0antibody\u00a0or\u00a0antibody\u00a0moiety,\u00a0which\u00a0is\u00a0determinative\u00a0of\u00a0the\u00a0presence\u00a0of\u00a0the\u00a0target\u00a0in\u00a0the\u00a0presence\u00a0of\u00a0a\u00a0heterogeneous\u00a0population\u00a0of\u00a0molecules,\u00a0including\u00a0biological\u00a0molecules.\u00a0For\u00a0example,\u00a0an\u00a0antibody\u00a0or\u00a0antibody\u00a0moiety\u00a0that\u00a0specifically\u00a0recognizes\u00a0a\u00a0target\u00a0(which\u00a0can\u00a0be\u00a0an\u00a0epitope)\u00a0is\u00a0an\u00a0antibody\u00a0or\u00a0antibody\u00a0moiety\u00a0that\u00a0binds\u00a0this\u00a0target\u00a0with\u00a0greater\u00a0affinity,\u00a0greater\u00a0avidity,\u00a0greater\u00a0readiness,\u00a0and/or\u00a0greater\u00a0duration\u00a0than\u00a0its\u00a0bindings\u00a0to\u00a0other\u00a0targets.\u00a0In\u00a0some\u00a0embodiments,\u00a0the\u00a0extent\u00a0of\u00a0binding\u00a0of\u00a0an\u00a0antibody\u00a0to\u00a0an\u00a0unrelated\u00a0target\u00a0is\u00a0less\u00a0than\u00a0about\u00a010%of\u00a0the\u00a0binding\u00a0of\u00a0the\u00a0antibody\u00a0to\u00a0the\u00a0target\u00a0as\u00a0measured,\u00a0e.g.,\u00a0by\u00a0a\u00a0radioimmunoassay\u00a0(RIA)\u00a0.\u00a0In\u00a0some\u00a0embodiments,\u00a0an\u00a0antibody\u00a0that\u00a0specifically\u00a0binds\u00a0a\u00a0target\u00a0has\u00a0a\u00a0dissociation\u00a0constant\u00a0(K<sub>D</sub>)\u00a0of\u226410<sup>-5</sup>\u00a0M,\u00a0\u226410<sup>-6</sup>\u00a0M,\u00a0\u226410<sup>-7</sup>\u00a0M,\u00a0\u226410<sup>-8</sup>\u00a0M,\u00a0\u226410<sup>-9</sup>\u00a0M,\u00a0\u226410<sup>-10</sup>\u00a0M,\u00a0\u226410<sup>-11</sup>\u00a0M,\u00a0or\u226410<sup>-12</sup>\u00a0M.\u00a0In\u00a0some\u00a0embodiments,\u00a0an\u00a0antibody\u00a0specifically\u00a0binds\u00a0an\u00a0epitope\u00a0on\u00a0a\u00a0protein\u00a0that\u00a0is\u00a0conserved\u00a0among\u00a0the\u00a0protein\u00a0from\u00a0different\u00a0species.\u00a0In\u00a0some\u00a0embodiments,\u00a0specific\u00a0binding\u00a0can\u00a0include,\u00a0but\u00a0does\u00a0not\u00a0require\u00a0exclusive\u00a0binding.\u00a0Binding\u00a0specificity\u00a0of\u00a0the\u00a0antibody\u00a0or\u00a0antigen-binding\u00a0domain\u00a0can\u00a0be\u00a0determined\u00a0experimentally\u00a0by\u00a0methods\u00a0known\u00a0in\u00a0the\u00a0art.\u00a0Such\u00a0methods\u00a0comprise,\u00a0but\u00a0are\u00a0not\u00a0limited\u00a0to\u00a0Western\u00a0blots,\u00a0ELISA-,\u00a0RIA-,\u00a0ECL-,\u00a0IRMA-,\u00a0EIA-,\u00a0BIACORE<sup>TM</sup>-tests\u00a0and\u00a0peptide\u00a0scans.</p><p id=\"p0079\" num=\"0079\">An\u00a0\u201cisolated\u201d\u00a0antibody\u00a0(or\u00a0construct)\u00a0is\u00a0one\u00a0that\u00a0has\u00a0been\u00a0identified,\u00a0separated\u00a0and/or\u00a0recovered\u00a0from\u00a0a\u00a0component\u00a0of\u00a0its\u00a0production\u00a0environment\u00a0(e.g.,\u00a0natural\u00a0or\u00a0recombinant)\u00a0.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0isolated\u00a0polypeptide\u00a0is\u00a0free\u00a0or\u00a0substantially\u00a0free\u00a0from\u00a0association\u00a0with\u00a0all\u00a0other\u00a0components\u00a0from\u00a0its\u00a0production\u00a0environment.</p><p id=\"p0080\" num=\"0080\">An\u00a0\u201cisolated\u201d\u00a0nucleic\u00a0acid\u00a0molecule\u00a0encoding\u00a0a\u00a0construct,\u00a0antibody,\u00a0or\u00a0antigen-binding\u00a0fragment\u00a0thereof\u00a0described\u00a0herein\u00a0is\u00a0a\u00a0nucleic\u00a0acid\u00a0molecule\u00a0that\u00a0is\u00a0identified\u00a0and\u00a0separated\u00a0from\u00a0at\u00a0least\u00a0one\u00a0contaminant\u00a0nucleic\u00a0acid\u00a0molecule\u00a0with\u00a0which\u00a0it\u00a0is\u00a0ordinarily\u00a0associated\u00a0in\u00a0the\u00a0environment\u00a0in\u00a0which\u00a0it\u00a0was\u00a0produced.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0isolated\u00a0nucleic\u00a0acid\u00a0is\u00a0free\u00a0or\u00a0substantially\u00a0free\u00a0from\u00a0association\u00a0w",
    "subject,\u00a0whereby\u00a0reduces\u00a0tumor\u00a0growth\u00a0and/or\u00a0lengthen\u00a0the\u00a0survival\u00a0of\u00a0a\u00a0subject.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0anti-B7H3\u00a0antibody\u00a0increases\u00a0an\u00a0immune\u00a0response\u00a0and/or\u00a0an\u00a0antitumor\u00a0effect\u00a0of\u00a0an\u00a0immune\u00a0cell,\u00a0e.g.,\u00a0a\u00a0T\u00a0cell\u00a0and/or\u00a0a\u00a0NK\u00a0cell.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0anti-B7H3\u00a0antibody\u00a0comprising\u00a0a\u00a0single\u00a0domain\u00a0antibody\u00a0(e.g.,\u00a0a\u00a0VHH)\u00a0has\u00a0a\u00a0smaller\u00a0molecule\u00a0size\u00a0compared\u00a0to\u00a0a\u00a0full-length\u00a0antibody\u00a0due\u00a0to\u00a0the\u00a0smaller\u00a0size\u00a0of\u00a0a\u00a0single\u00a0domain\u00a0antibody\u00a0compared\u00a0to\u00a0a\u00a0Fab\u00a0domain\u00a0of\u00a0a\u00a0full-length\u00a0antibody,\u00a0which\u00a0can\u00a0result\u00a0in\u00a0superior\u00a0tissue\u00a0infiltration,\u00a0e.g.,\u00a0at\u00a0a\u00a0tumor\u00a0site,\u00a0compared\u00a0to\u00a0a\u00a0full-length\u00a0antibody.\u00a0In\u00a0certain\u00a0embodiments,\u00a0treatment\u00a0using\u00a0the\u00a0anti-B7H3\u00a0antibody\u00a0exhibits\u00a0superior\u00a0antitumor\u00a0efficacy\u00a0compared\u00a0to\u00a0treatment\u00a0using\u00a0a\u00a0full-length\u00a0anti-B7H3\u00a0antibody,\u00a0e.g.,\u00a0analogs\u00a0of\u00a0MGA-271\u00a0(also\u00a0\t\t\t\t<!-- 25 -->\n\t\t\t\t\nknown\u00a0as\u00a0enoblituzumab)\u00a0and/or\u00a0h1702,\u00a0which\u00a0sequences\u00a0are\u00a0disclosed\u00a0in\u00a0US\u00a08,\u00a0802,\u00a0091\u00a0and\u00a0US\u00a020200031934\u00a0A1,\u00a0respectively.</p><p id=\"p0115\" num=\"0115\">In\u00a0certain\u00a0embodiments,\u00a0the\u00a0anti-B7H3\u00a0antibody\u00a0comprises\u00a0a\u00a0single\u00a0domain\u00a0antibody\u00a0that\u00a0binds\u00a0to\u00a0B7H3.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0comprises\u00a0a\u00a0VHH.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0comprises\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0(VH)\u00a0.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0is\u00a0linked\u00a0to\u00a0a\u00a0Fc\u00a0region.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0is\u00a0not\u00a0linked\u00a0to\u00a0a\u00a0Fc\u00a0region.</p><p id=\"p0116\" num=\"0116\">In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0about\u00a01x10<sup>-7</sup>\u00a0M\u00a0or\u00a0less.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0about\u00a01x10<sup>-8</sup>\u00a0M\u00a0or\u00a0less.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0about\u00a05x10<sup>-9</sup>\u00a0M\u00a0or\u00a0less.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0about\u00a01x10<sup>-9</sup>\u00a0M\u00a0or\u00a0less.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0about\u00a01x10<sup>-10</sup>\u00a0M\u00a0or\u00a0less.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0between\u00a0about\u00a01x10<sup>-11</sup>\u00a0M\u00a0and\u00a0about\u00a01x10<sup>-7</sup>\u00a0M.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0between\u00a0about\u00a01x10<sup>-10</sup>M\u00a0and\u00a0about\u00a01x10<sup>-7</sup>M.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0between\u00a0about\u00a01x10<sup>-10</sup>\u00a0M\u00a0and\u00a0about\u00a01x10<sup>-8</sup>\u00a0M.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0between\u00a0about\u00a01x10<sup>-11</sup>\u00a0M\u00a0and\u00a0about\u00a01x10<sup>-9</sup>\u00a0M.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0between\u00a0about\u00a02x10<sup>-10</sup>\u00a0M\u00a0and\u00a0about\u00a05x10<sup>-9</sup>\u00a0M.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0between\u00a0about\u00a01x10<sup>-9</sup>\u00a0M\u00a0and\u00a0about\u00a05x10<sup>-</sup>\n<sup>8</sup>\u00a0M.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0binds\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0between\u00a0about\u00a01x10<sup>-10</sup>\u00a0M\u00a0and\u00a0about\u00a01x10<sup>-9</sup>\u00a0M.</p><p id=\"p0117\" num=\"0117\">In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0cross-competes\u00a0for\u00a0binding\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0reference\u00a0anti-B7H3\u00a0single\u00a0domain\u00a0antibody\u00a0comprising\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR1\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a01,\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR2\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a02,\u00a0and\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR3\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a03.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0antibody\u00a0cross-competes\u00a0for\u00a0binding\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0reference\u00a0anti-B7H3\u00a0single\u00a0domain\u00a0antibody\u00a0comprising\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR1\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a05,\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR2\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a06,\u00a0and\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR3\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a07.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0single\u00a0domain\u00a0\t\t\t\t<!-- 26 -->\n\t\t\t\t\nantibody\u00a0cross-competes\u00a0for\u00a0binding\u00a0to\u00a0B7H3\u00a0with\u00a0a\u00a0reference\u00a0anti-B7H3\u00a0single\u00a0domain\u00a0antibody\u00a0comprising\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR1\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a09,\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR2\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0forth\u00a0in\u00a0SEQ\u00a0ID\u00a0NO:\u00a010,\u00a0and\u00a0a\u00a0heavy\u00a0chain\u00a0variable\u00a0region\u00a0CDR3\u00a0comprising\u00a0amino\u00a0acids\u00a0having\u00a0the\u00a0sequence\u00a0set\u00a0for",
    "te-binding\u00a0protein\u00a0(FBP)\u00a0,\u00a0fetal\u00a0acetylcholine\u00a0receptor\u00a0(AChR)\u00a0,\u00a0folate\u00a0receptor-a,\u00a0Ganglioside\u00a0G2\u00a0(GD2)\u00a0,\u00a0Ganglioside\u00a0G3\u00a0(GD3)\u00a0,\u00a0human\u00a0telomerase\u00a0reverse\u00a0transcriptase\u00a0(hTERT)\u00a0,\u00a0kinase\u00a0insert\u00a0domain\u00a0receptor\u00a0(KDR)\u00a0,\u00a0Lewis\u00a0A\u00a0(CA\u00a01.9.9)\u00a0,\u00a0Lewis\u00a0Y\u00a0(LeY)\u00a0,\u00a0Glypican-3\u00a0(GPC3)\u00a0,\u00a0L1\u00a0cell\u00a0adhesion\u00a0molecule\u00a0(L1CAM)\u00a0,\u00a0Mucin\u00a016\u00a0(Muc-16)\u00a0,\u00a0Mucin\u00a01\u00a0(Muc-1)\u00a0,\u00a0NG2D\u00a0ligands,\u00a0oncofetal\u00a0antigen\u00a0(h5T4)\u00a0,\u00a0prostate\u00a0stem\u00a0cell\u00a0antigen\u00a0(PSCA)\u00a0,\u00a0prostate-specific\u00a0membrane\u00a0antigen\u00a0(PSMA)\u00a0,\u00a0tumor-associated\u00a0glycoprotein\u00a072\u00a0(TAG-72)\u00a0,\u00a0Claudin18.2\u00a0(CLDN18.2)\u00a0,\u00a0vascular\u00a0endothelial\u00a0growth\u00a0factor\u00a0R2\u00a0(VEGF-R2)\u00a0,\u00a0Wilms\u00a0tumor\u00a0protein\u00a0(WT-1)\u00a0,\u00a0type\u00a01\u00a0tyrosine-protein\u00a0kinase\u00a0transmembrane\u00a0receptor\u00a0(ROR1)\u00a0,\u00a0PVR,\u00a0PVRL2\u00a0and\u00a0any\u00a0combination\u00a0thereof.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0second\u00a0antigen\u00a0is\u00a0an\u00a0immune\u00a0checkpoint\u00a0regulator.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0immune\u00a0checkpoint\u00a0regulator\u00a0is\u00a0selected\u00a0from\u00a0the\u00a0group\u00a0consisting\u00a0of\u00a0TIGIT,\u00a0PD1,\u00a0CTLA4,\u00a0LAG-3,\u00a02B4,\u00a0BTLA\u00a0and\u00a0any\u00a0combination\u00a0thereof.</p><p id=\"p0129\" num=\"0129\">In\u00a0certain\u00a0embodiments,\u00a0the\u00a0anti-B7H3\u00a0antibody\u00a0is\u00a0conjugated\u00a0to\u00a0a\u00a0therapeutic\u00a0agent\u00a0or\u00a0a\u00a0label.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0label\u00a0is\u00a0selected\u00a0from\u00a0the\u00a0group\u00a0consisting\u00a0of\u00a0a\u00a0radioisotope,\u00a0a\u00a0fluorescent\u00a0dye\u00a0and\u00a0an\u00a0enzyme.</p><p id=\"p0130\" num=\"0130\">2.2\u00a0Antibody\u00a0Affinity</p><p id=\"p0131\" num=\"0131\">In\u00a0certain\u00a0embodiments,\u00a0an\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0disclosed\u00a0herein\u00a0has\u00a0a\u00a0high\u00a0binding\u00a0affinity\u00a0to\u00a0its\u00a0target\u00a0antigen.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0binds\u00a0to\u00a0the\u00a0target\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0about\u00a01x10<sup>-7</sup>M\u00a0or\u00a0less.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0binds\u00a0to\u00a0the\u00a0target\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0about\u00a01x10<sup>-8</sup>\u00a0M\u00a0or\u00a0less.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0binds\u00a0to\u00a0the\u00a0target\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0about\u00a05x10<sup>-9</sup>\u00a0M\u00a0or\u00a0less.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0binds\u00a0to\u00a0the\u00a0target\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0about\u00a01x10<sup>-9</sup>\u00a0M\u00a0or\u00a0less.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0binds\u00a0to\u00a0the\u00a0target\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0about\u00a01x10<sup>-10</sup>\u00a0M\u00a0or\u00a0less.</p><p id=\"p0132\" num=\"0132\">In\u00a0certain\u00a0embodiments,\u00a0the\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0binds\u00a0to\u00a0the\u00a0target\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0between\u00a0about\u00a01x10<sup>-11</sup>\u00a0M\u00a0and\u00a0about\u00a01x10<sup>-7</sup>\u00a0M.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0binds\u00a0to\u00a0the\u00a0target\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0between\u00a0about\u00a01x10<sup>-10</sup>\u00a0M\u00a0and\u00a0about\u00a01x10<sup>-</sup>\n<sup>7</sup>\u00a0M.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0binds\u00a0to\u00a0the\u00a0target\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0between\u00a0about\u00a01x10<sup>-10</sup>\u00a0M\u00a0and\u00a0about\u00a01x10<sup>-8</sup>\u00a0M.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0binds\u00a0to\u00a0the\u00a0target\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0between\u00a0about\u00a01x10<sup>-11</sup>\u00a0M\u00a0and\u00a0about\u00a01x10<sup>-</sup>\n<sup>9</sup>\u00a0M.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0binds\u00a0to\u00a0the\u00a0target\u00a0with\u00a0a\u00a0KD\u00a0\t\t\t\t<!-- 33 -->\n\t\t\t\t\nof\u00a0between\u00a0about\u00a02x10<sup>-10</sup>\u00a0M\u00a0and\u00a0about\u00a05x10<sup>-9</sup>\u00a0M.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0binds\u00a0to\u00a0the\u00a0target\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0between\u00a0about\u00a01x10<sup>-9</sup>\u00a0M\u00a0and\u00a0about\u00a05x10<sup>-8</sup>\u00a0M.\u00a0In\u00a0certain\u00a0embodiments,\u00a0the\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0binds\u00a0to\u00a0the\u00a0target\u00a0with\u00a0a\u00a0KD\u00a0of\u00a0between\u00a0about\u00a01x10<sup>-10</sup>\u00a0M\u00a0and\u00a0about\u00a01x10<sup>-9</sup>\u00a0M.</p><p id=\"p0133\" num=\"0133\">The\u00a0KD\u00a0of\u00a0the\u00a0antibody\u00a0or\u00a0antibody\u00a0derivative\u00a0can\u00a0be\u00a0determined\u00a0by\u00a0methods\u00a0known\u00a0in\u00a0the\u00a0art.\u00a0Such\u00a0methods\u00a0comprise,\u00a0but\u00a0are\u00a0not\u00a0limited\u00a0to\u00a0Western\u00a0blots,\u00a0ELISA-,\u00a0RIA-,\u00a0ECL-,\u00a0IRMA-,\u00a0EIA-,\u00a0<img id=\"idf0004\" path=\"PCTCN2023120292-ftappb-I100004.jpg\" file=\"https://surechembl.org/api/assets/attachment/1228453348/WO/20240328/A1/002024/06/13/06/PCTCN2023120292-ftappb-I100004.jpg\"/>and\u00a0peptide\u00a0scans.</p><p id=\"p0134\" num=\"0134\">In\u00a0certain\u00a0embodiments,\u00a0KD\u00a0can\u00a0be\u00a0measured\u00a0using\u00a0a<img id=\"idf0005\" path=\"PCTCN2023120292-ftappb-I100005.jpg\" file=\"https://surechembl.org/api/assets/attachment/1228453349/WO/20240328/A1/002024/06/13/06/PCTCN2023120292-ftappb-I100005.jpg\"/>surface\u00a0plasmon\u00a0resonance\u00a0assay.\u00a0For\u00a0example,\u00a0and\u00a0not\u00a0by\u00a0way\u00a0of\u00a0limitation,\u00a0an\u00a0assay\u00a0using\u00a0a<img id=\"idf0006\" path=\"PCTCN2023120292-ftappb-I100006.jpg\" file=\"https://surechembl.org/api/assets/attachment/1228453350/WO/20240328/A1/002024/06/13/06/PCTCN2023120292-ftappb-I100006.jpg\"/>\n<img id=\"idf0007\" path=\"PCTCN2023120292-ftappb-I100007.jpg\" file=\"https://surechembl.org/api/assets/attachment/1228453351/WO/20240328/A1/002024/06/13/06/PCTCN2023120292-ftappb-I100007.jpg\"/>or\u00a0a<img id=\"idf0008\" path=\"PCTCN2023120292-ftappb-I100008.jpg\" file=\"https://surechembl.org/api/assets/attachment/1228453352/WO/20240328/A1/002024/06/13/06/PCTCN2023120292-ftappb-I100008.jpg\"/>3000\u00a0(Biacore,\u00a0Inc.,\u00a0Piscataway,\u00a0NJ)\u00a0is\u00a0performed\u00a0at\u00a025\u2103\u00a0with\u00a0immobilized\u00a0antigen\u00a0CMS\u00a0chips\u00a0at\u00a0about\u00a010\u00a0response\u00a0units\u00a0(RU)\u00a0.\u00a0In\u00a0certain\u00a0embodiments,\u00a0carboxymethylated\u00a0dextran\u00a0biosensor\u00a0chips\u00a0(CMS,\u00a0Biacore,\u00a0Inc.\u00a0)\u00a0are\u00a0activated\u00a0with\u00a0N-ethyl-N'-\u00a0(3-dimethylaminopropyl)\u00a0-carbodiimide\u00a0hydrochloride\u00a0(EDC)\u00a0and\u00a0N-hydroxysuccinimide\u00a0(NHS)\u00a0according\u00a0to\u00a0the\u00a0supplier's\u00a0instructions.\u00a0Antigen\u00a0is\u00a0diluted\u00a0with\u00a010\u00a0mM\u00a0sodium\u00a0acetate,\u00a0pH\u00a04.8,\u00a0to\u00a05\u03bcg/ml\u00a0(about\u00a00.2\u03bcM)\u00a0before\u00a0injection\u00a0at\u00a0a\u00a0flow\u00a0rate\u00a0of\u00a05\u03bcl/minute\u00a0to\u00a0achieve\u00a0approximately\u00a010\u00a0response\u00a0units\u00a0(RU)\u00a0of\u00a0coupled\u00a0protein.\u00a0Following\u00a0the\u00a0injection\u00a0of\u00a0antigen,\u00a01\u00a0M\u00a0ethanolamine\u00a0is\u00a0injected\u00a0to\u00a0block\u00a0unreacted\u00a0groups.\u00a0For\u00a0kinetics\u00a0measurements,\u00a0two-fold\u00a0serial\u00a0dilutions\u00a0of\u00a0Fab\u00a0(0.78\u00a0nM\u00a0to\u00a0500\u00a0nM)\u00a0are\u00a0injected\u00a0in\u00a0PBS\u00a0with\u00a00.05%polysorbate\u00a020\u00a0(TWEEN-20TM)\u00a0surfactant\u00a0(PBST)\u00a0at\u00a025\u2103\u00a0at\u00a0a\u00a0flow\u00a0rate\u00a0of\u00a0approximately\u00a025\u03bcl/min.\u00a0Association\u00a0rates\u00a0(k<sub>on</sub>)\u00a0and\u00a0dissociation\u00a0rates\u00a0(k<sub>off</sub>)\u00a0are\u00a0calculated\u00a0using\u00a0a\u00a0simple\u00a0one-to-one\u00a0Langmuir\u00a0binding\u00a0model\u00a0(<img id=\"idf0009\" path=\"PCTCN2023120292-ftappb-I100009.jpg\" file=\"https://surechembl.org/api/assets/attachment/1228453353/WO/20240328/A1/002024/06/13/06/PCTCN2023120292-ftappb-I100009.jpg\"/>Evaluation\u00a0Software\u00a0version\u00a03.2)\u00a0by\u00a0simultaneously\u00a0fitting\u00a0the\u00a0association\u00a0and\u00a0dissociation\u00a0sensorgrams.\u00a0The\u00a0equilibrium\u00a0dissociation\u00a0constant\u00a0(KD)\u00a0can\u00a0be\u00a0calculated\u00a0as\u00a0the\u00a0ratio\u00a0koff/kon.\u00a0See,\u00a0e.g.,\u00a0Chen\u00a0et\u00a0al.,\u00a0J.\u00a0Mol.\u00a0Biol.\u00a0293:\u00a0865-881\u00a0(1999)\u00a0.\u00a0Ifthe\u00a0on-rate\u00a0exceeds\u00a010<sup>6</sup>\u00a0M<sup>-l</sup>\u00a0s<sup>-1</sup>\u00a0by\u00a0the\u00a0surface\u00a0plasmon\u00a0resonance\u00a0assay\u00a0above,\u00a0then\u00a0the\u00a0on-rate\u00a0can\u00a0be\u00a0determined\u00a0by\u00a0using\u00a0a\u00a0fluorescent\u00a0quenching\u00a0technique\u00a0that\u00a0measures\u00a0the\u00a0increase\u00a0or\u00a0decrease\u00a0in\u00a0fluorescence\u00a0emission\u00a0intensity\u00a0(excitation=295\u00a0nm;\u00a0emission=340\u00a0nm,16\u00a0nm\u00a0band-pass)\u00a0at\u00a025\u2103\u00a0of\u00a0a\u00a020\u00a0nM\u00a0anti-antigen\u00a0antibody\u00a0(Fab\u00a0form)\u00a0in\u00a0PBS,\u00a0pH\u00a07.2,\u00a0in\u00a0the\u00a0presence\u00a0of\u00a0increasing\u00a0concentrations\u00a0of\u00a0antigen\u00a0as\u00a0measured\u00a0in\u00a0a\u00a0spectrometer,\u00a0such\u00a0as\u00a0a\u00a0stop-flow\u00a0equipped\u00a0spectrophometer\u00a0(Aviv\u00a0Instruments)\u00a0or\u00a0a\u00a08000-series\u00a0SLM-AMINCO<sup>TM</sup>\u00a0spectrophotometer\u00a0(ThermoSpectronic)\u00a0with\u00a0a\u00a0stirred\u00a0cuvette.</p><p id=\"p0135\" num=\"0135\">2.3\u00a0Antibody\u00a0Fragments</p><p id=\"p0136\" num=\"0136\">In\u00a0certain\u00a0embodiments,\u00a0an\u00a0antibody\u00a0of\u00a0the\u00a0present\u00a0disclosure\u00a0comprises\u00a0an\u00a0antigen-binding\u00a0fragment\u00a0or\u00a0antibody\u00a0fragment.\u00a0Antibody\u00a0fragments\u00a0include,\u00a0but\u00a0are\u00a0not\u00a0limited\u00a0to,\u00a0\t\t\t\t<!-- 34 -->\n\t\t\t\t\nFab,\u00a0Fab',\u00a0Fab'-SH,\u00a0F\u00a0(ab')\u00a02,\u00a0VHH,\u00a0Fv,\u00a0and\u00a0scFv\u00a0fragments,\u00a0and\u00a0other\u00a0fragments\u00a0described\u00a0herein.\u00a0For\u00a0a\u00a0review\u00a0of\u00a0certain\u00a0antibody\u00a0fragments,\u00a0see\u00a0Hudson\u00a0et\u00a0al.\u00a0Nat.\u00a0Med.\u00a09:\u00a0129-134\u00a0(2003)\u00a0.\u00a0For\u00a0a\u00a0review\u00a0of\u00a0scFv\u00a0fragments,\u00a0see\u00a0e.g.,\u00a0Pluckthtin,\u00a0in\u00a0The\u00a0Pharmacology\u00a0of\u00a0Monoclonal\u00a0Antibodies,\u00a0vol.\u00a0113,\u00a0Rosenburg\u00a0and\u00a0Moore\u00a0eds.,\u00a0(Springer-Verlag,\u00a0New\u00a0York)\u00a0,\u00a0pp.269-31\u00a05\u00a0(1994)\u00a0;\u00a0see\u00a0also\u00a0WO\u00a093/16185;\u00a0and\u00a0U.S.\u00a0Patent\u00a0Nos.\u00a05,571,894\u00a0and\u00a05,587,458.\u00a0For\u00a0discussion\u00a0of\u00a0Fab\u00a0and\u00a0F\u00a0(ab)\u00a0<sub>"
]